NO147913B - Analogifremgangsmaate for fremstilling av fysiologisk aktive pyrazolopyridiner - Google Patents
Analogifremgangsmaate for fremstilling av fysiologisk aktive pyrazolopyridiner Download PDFInfo
- Publication number
- NO147913B NO147913B NO773327A NO773327A NO147913B NO 147913 B NO147913 B NO 147913B NO 773327 A NO773327 A NO 773327A NO 773327 A NO773327 A NO 773327A NO 147913 B NO147913 B NO 147913B
- Authority
- NO
- Norway
- Prior art keywords
- phenyl
- nicotinonitrile
- chloro
- melting point
- pyrazolo
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 3
- 150000005229 pyrazolopyridines Chemical class 0.000 title 1
- -1 ethylamino- Chemical class 0.000 claims description 67
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 150000007522 mineralic acids Chemical class 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- 235000005985 organic acids Nutrition 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- GVLRTOYGRNLSDW-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyridine Chemical class C1=CC=C2C=NNC2=N1 GVLRTOYGRNLSDW-UHFFFAOYSA-N 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 claims description 2
- 230000000269 nucleophilic effect Effects 0.000 claims description 2
- 230000008018 melting Effects 0.000 description 83
- 238000002844 melting Methods 0.000 description 83
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 45
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000001816 cooling Methods 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000007795 chemical reaction product Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- RKCOTKNKKXMGTC-UHFFFAOYSA-N 2-hydroxy-6-oxo-4-phenyl-1h-pyridine-3-carbonitrile Chemical compound N#CC1=C(O)NC(=O)C=C1C1=CC=CC=C1 RKCOTKNKKXMGTC-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- CVTJKFRXMJAKEV-UHFFFAOYSA-N 6-morpholin-4-yl-4-phenyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C=12C(N)=NNC2=NC(N2CCOCC2)=CC=1C1=CC=CC=C1 CVTJKFRXMJAKEV-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 4
- OEVQDTLHJYEGEI-UHFFFAOYSA-N 2,6-dichloro-4-phenylpyridine-3-carbonitrile Chemical compound ClC1=NC(Cl)=CC(C=2C=CC=CC=2)=C1C#N OEVQDTLHJYEGEI-UHFFFAOYSA-N 0.000 description 3
- RVZCHQBSEJWZHT-UHFFFAOYSA-N 2-chloro-6-morpholin-4-yl-4-phenylpyridine-3-carbonitrile Chemical compound N#CC=1C(Cl)=NC(N2CCOCC2)=CC=1C1=CC=CC=C1 RVZCHQBSEJWZHT-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- ZGXJWDSHZMPFHN-UHFFFAOYSA-N 2-bromo-6-morpholin-4-yl-4-phenylpyridine-3-carbonitrile Chemical compound N#CC=1C(Br)=NC(N2CCOCC2)=CC=1C1=CC=CC=C1 ZGXJWDSHZMPFHN-UHFFFAOYSA-N 0.000 description 2
- QYBVNSPKRUGHII-UHFFFAOYSA-N 2-chloro-4-(2-fluorophenyl)-6-morpholin-4-ylpyridine-3-carbonitrile Chemical compound FC1=CC=CC=C1C1=CC(N2CCOCC2)=NC(Cl)=C1C#N QYBVNSPKRUGHII-UHFFFAOYSA-N 0.000 description 2
- XQEFQKWYMUWOFS-UHFFFAOYSA-N 2-chloro-4-(4-chlorophenyl)-6-morpholin-4-ylpyridine-3-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C1=CC(N2CCOCC2)=NC(Cl)=C1C#N XQEFQKWYMUWOFS-UHFFFAOYSA-N 0.000 description 2
- HHJPGLFCHSSEHK-UHFFFAOYSA-N 2-chloro-4-(4-fluorophenyl)-6-morpholin-4-ylpyridine-3-carbonitrile Chemical compound C1=CC(F)=CC=C1C1=CC(N2CCOCC2)=NC(Cl)=C1C#N HHJPGLFCHSSEHK-UHFFFAOYSA-N 0.000 description 2
- JGBAOKFGECLZTB-UHFFFAOYSA-N 2-chloro-4-phenyl-6-(4-phenylpiperazin-1-yl)pyridine-3-carbonitrile Chemical compound N#CC=1C(Cl)=NC(N2CCN(CC2)C=2C=CC=CC=2)=CC=1C1=CC=CC=C1 JGBAOKFGECLZTB-UHFFFAOYSA-N 0.000 description 2
- GFEBDBWRMUPQQO-UHFFFAOYSA-N 2-chloro-4-phenyl-6-(propan-2-ylamino)pyridine-3-carbonitrile Chemical compound ClC1=NC(NC(C)C)=CC(C=2C=CC=CC=2)=C1C#N GFEBDBWRMUPQQO-UHFFFAOYSA-N 0.000 description 2
- ZTFFLEBEFDWFGM-UHFFFAOYSA-N 2-chloro-4-phenyl-6-piperidin-1-ylpyridine-3-carbonitrile Chemical compound N#CC=1C(Cl)=NC(N2CCCCC2)=CC=1C1=CC=CC=C1 ZTFFLEBEFDWFGM-UHFFFAOYSA-N 0.000 description 2
- WUYJRVBIBIUMDU-UHFFFAOYSA-N 2-chloro-4-phenyl-6-pyrrolidin-1-ylpyridine-3-carbonitrile Chemical compound N#CC=1C(Cl)=NC(N2CCCC2)=CC=1C1=CC=CC=C1 WUYJRVBIBIUMDU-UHFFFAOYSA-N 0.000 description 2
- UGXSCEGVFSITAL-UHFFFAOYSA-N 2-chloro-4-phenyl-6-thiomorpholin-4-ylpyridine-3-carbonitrile Chemical compound N#CC=1C(Cl)=NC(N2CCSCC2)=CC=1C1=CC=CC=C1 UGXSCEGVFSITAL-UHFFFAOYSA-N 0.000 description 2
- KPOZKEXKXFBVHD-UHFFFAOYSA-N 2-chloro-6-(1-oxo-1,4-thiazinan-4-yl)-4-phenylpyridine-3-carbonitrile Chemical compound N#CC=1C(Cl)=NC(N2CCS(=O)CC2)=CC=1C1=CC=CC=C1 KPOZKEXKXFBVHD-UHFFFAOYSA-N 0.000 description 2
- CRWWVLZWZIGCBT-UHFFFAOYSA-N 2-chloro-6-(2,6-dimethylmorpholin-4-yl)-4-phenylpyridine-3-carbonitrile Chemical compound C1C(C)OC(C)CN1C1=CC(C=2C=CC=CC=2)=C(C#N)C(Cl)=N1 CRWWVLZWZIGCBT-UHFFFAOYSA-N 0.000 description 2
- JWLRLSFMPKHCAU-UHFFFAOYSA-N 2-chloro-6-(2,6-dimethylpiperidin-1-yl)-4-phenylpyridine-3-carbonitrile Chemical compound CC1CCCC(C)N1C1=CC(C=2C=CC=CC=2)=C(C#N)C(Cl)=N1 JWLRLSFMPKHCAU-UHFFFAOYSA-N 0.000 description 2
- VWPUWYOVVNEZJG-UHFFFAOYSA-N 2-chloro-6-(2,6-dimethylthiomorpholin-4-yl)-4-phenylpyridine-3-carbonitrile Chemical compound C1C(C)SC(C)CN1C1=CC(C=2C=CC=CC=2)=C(C#N)C(Cl)=N1 VWPUWYOVVNEZJG-UHFFFAOYSA-N 0.000 description 2
- MIYVVFCBSNPIHW-UHFFFAOYSA-N 2-chloro-6-(2-methyl-1-oxo-1,4-thiazinan-4-yl)-4-phenylpyridine-3-carbonitrile Chemical compound C1CS(=O)C(C)CN1C1=CC(C=2C=CC=CC=2)=C(C#N)C(Cl)=N1 MIYVVFCBSNPIHW-UHFFFAOYSA-N 0.000 description 2
- RVLMVZXPSQJSPN-UHFFFAOYSA-N 2-chloro-6-(2-methylmorpholin-4-yl)-4-phenylpyridine-3-carbonitrile Chemical compound C1COC(C)CN1C1=CC(C=2C=CC=CC=2)=C(C#N)C(Cl)=N1 RVLMVZXPSQJSPN-UHFFFAOYSA-N 0.000 description 2
- XAHBCXFXYNUMCB-UHFFFAOYSA-N 2-chloro-6-(2-methylpiperidin-1-yl)-4-phenylpyridine-3-carbonitrile Chemical compound CC1CCCCN1C1=CC(C=2C=CC=CC=2)=C(C#N)C(Cl)=N1 XAHBCXFXYNUMCB-UHFFFAOYSA-N 0.000 description 2
- UJTKHGQTXDQKSZ-UHFFFAOYSA-N 2-chloro-6-(3-hydroxypiperidin-1-yl)-4-phenylpyridine-3-carbonitrile Chemical compound C1C(O)CCCN1C1=CC(C=2C=CC=CC=2)=C(C#N)C(Cl)=N1 UJTKHGQTXDQKSZ-UHFFFAOYSA-N 0.000 description 2
- HNRVXAWDWJHYCF-UHFFFAOYSA-N 2-chloro-6-(3-methylbutylamino)-4-phenylpyridine-3-carbonitrile Chemical compound ClC1=NC(NCCC(C)C)=CC(C=2C=CC=CC=2)=C1C#N HNRVXAWDWJHYCF-UHFFFAOYSA-N 0.000 description 2
- DLGYLCIXDJFEHH-UHFFFAOYSA-N 2-chloro-6-(3-methylpiperidin-1-yl)-4-phenylpyridine-3-carbonitrile Chemical compound C1C(C)CCCN1C1=CC(C=2C=CC=CC=2)=C(C#N)C(Cl)=N1 DLGYLCIXDJFEHH-UHFFFAOYSA-N 0.000 description 2
- XWIADIWZYYOKND-UHFFFAOYSA-N 2-chloro-6-(4-formylpiperazin-1-yl)-4-phenylpyridine-3-carbonitrile Chemical compound N#CC=1C(Cl)=NC(N2CCN(CC2)C=O)=CC=1C1=CC=CC=C1 XWIADIWZYYOKND-UHFFFAOYSA-N 0.000 description 2
- XWQAPXRTGMHFOU-UHFFFAOYSA-N 2-chloro-6-(4-methylpiperazin-1-yl)-4-phenylpyridine-3-carbonitrile Chemical compound C1CN(C)CCN1C1=CC(C=2C=CC=CC=2)=C(C#N)C(Cl)=N1 XWQAPXRTGMHFOU-UHFFFAOYSA-N 0.000 description 2
- VQHHICXDFXGOFM-UHFFFAOYSA-N 2-chloro-6-(4-methylpiperidin-1-yl)-4-phenylpyridine-3-carbonitrile Chemical compound C1CC(C)CCN1C1=CC(C=2C=CC=CC=2)=C(C#N)C(Cl)=N1 VQHHICXDFXGOFM-UHFFFAOYSA-N 0.000 description 2
- HOMHBXNZJHPJTQ-UHFFFAOYSA-N 2-chloro-6-(dibutylamino)-4-phenylpyridine-3-carbonitrile Chemical compound ClC1=NC(N(CCCC)CCCC)=CC(C=2C=CC=CC=2)=C1C#N HOMHBXNZJHPJTQ-UHFFFAOYSA-N 0.000 description 2
- NISCUZSYMGZNRY-UHFFFAOYSA-N 2-chloro-6-(diethylamino)-4-phenylpyridine-3-carbonitrile Chemical compound ClC1=NC(N(CC)CC)=CC(C=2C=CC=CC=2)=C1C#N NISCUZSYMGZNRY-UHFFFAOYSA-N 0.000 description 2
- JCILWQSSMUFOJQ-UHFFFAOYSA-N 2-chloro-6-(dimethylamino)-4-phenylpyridine-3-carbonitrile Chemical compound ClC1=NC(N(C)C)=CC(C=2C=CC=CC=2)=C1C#N JCILWQSSMUFOJQ-UHFFFAOYSA-N 0.000 description 2
- ABYZCKYNTJMPFA-UHFFFAOYSA-N 2-chloro-6-(dipropylamino)-4-phenylpyridine-3-carbonitrile Chemical compound ClC1=NC(N(CCC)CCC)=CC(C=2C=CC=CC=2)=C1C#N ABYZCKYNTJMPFA-UHFFFAOYSA-N 0.000 description 2
- XAUMBNQAWQLYJL-UHFFFAOYSA-N 2-chloro-6-(ethylamino)-4-phenylpyridine-3-carbonitrile Chemical compound ClC1=NC(NCC)=CC(C=2C=CC=CC=2)=C1C#N XAUMBNQAWQLYJL-UHFFFAOYSA-N 0.000 description 2
- HJYTXRHWERXMDX-UHFFFAOYSA-N 2-chloro-6-[3-(hydroxymethyl)piperidin-1-yl]-4-phenylpyridine-3-carbonitrile Chemical compound C1C(CO)CCCN1C1=CC(C=2C=CC=CC=2)=C(C#N)C(Cl)=N1 HJYTXRHWERXMDX-UHFFFAOYSA-N 0.000 description 2
- LHAYHPQZGVWYMU-UHFFFAOYSA-N 2-chloro-6-[cyclohexyl(methyl)amino]-4-phenylpyridine-3-carbonitrile Chemical compound C=1C(C=2C=CC=CC=2)=C(C#N)C(Cl)=NC=1N(C)C1CCCCC1 LHAYHPQZGVWYMU-UHFFFAOYSA-N 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 2
- 229940093475 2-ethoxyethanol Drugs 0.000 description 2
- NPZHPAGIHWDLIA-UHFFFAOYSA-N 4-phenyl-6-piperidin-1-yl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C=12C(N)=NNC2=NC(N2CCCCC2)=CC=1C1=CC=CC=C1 NPZHPAGIHWDLIA-UHFFFAOYSA-N 0.000 description 2
- BDGXZMZUBTVABI-UHFFFAOYSA-N 4-phenyl-6-thiomorpholin-4-yl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical group C12=C(N)NN=C2N=C(N2CCSCC2)C=C1C1=CC=CC=C1 BDGXZMZUBTVABI-UHFFFAOYSA-N 0.000 description 2
- XHUILVQASNRAKP-UHFFFAOYSA-N 6-(4-benzylpiperazin-1-yl)-2-chloro-4-phenylpyridine-3-carbonitrile Chemical compound N#CC=1C(Cl)=NC(N2CCN(CC=3C=CC=CC=3)CC2)=CC=1C1=CC=CC=C1 XHUILVQASNRAKP-UHFFFAOYSA-N 0.000 description 2
- VUXUXMJIOXDKPR-UHFFFAOYSA-N 6-(4-benzylpiperidin-1-yl)-2-chloro-4-phenylpyridine-3-carbonitrile Chemical compound N#CC=1C(Cl)=NC(N2CCC(CC=3C=CC=CC=3)CC2)=CC=1C1=CC=CC=C1 VUXUXMJIOXDKPR-UHFFFAOYSA-N 0.000 description 2
- MXVUDLTYAUEQFX-UHFFFAOYSA-N 6-(azepan-1-yl)-2-chloro-4-phenylpyridine-3-carbonitrile Chemical compound N#CC=1C(Cl)=NC(N2CCCCCC2)=CC=1C1=CC=CC=C1 MXVUDLTYAUEQFX-UHFFFAOYSA-N 0.000 description 2
- HLNYBLDXKSUQNT-UHFFFAOYSA-N 6-(azepan-1-yl)-4-(4-fluorophenyl)-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C12=C(N)NN=C2N=C(N2CCCCCC2)C=C1C1=CC=C(F)C=C1 HLNYBLDXKSUQNT-UHFFFAOYSA-N 0.000 description 2
- WBWNBGWBTKSCSH-UHFFFAOYSA-N 6-(azepan-1-yl)-4-phenyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical group C12=C(N)NN=C2N=C(N2CCCCCC2)C=C1C1=CC=CC=C1 WBWNBGWBTKSCSH-UHFFFAOYSA-N 0.000 description 2
- PWLDRYLPFCNRES-UHFFFAOYSA-N 6-(benzylamino)-2-chloro-4-phenylpyridine-3-carbonitrile Chemical compound C=1C(C=2C=CC=CC=2)=C(C#N)C(Cl)=NC=1NCC1=CC=CC=C1 PWLDRYLPFCNRES-UHFFFAOYSA-N 0.000 description 2
- NCKQTBNRNCNWHE-UHFFFAOYSA-N 6-[benzyl(methyl)amino]-2-chloro-4-phenylpyridine-3-carbonitrile Chemical compound C=1C(C=2C=CC=CC=2)=C(C#N)C(Cl)=NC=1N(C)CC1=CC=CC=C1 NCKQTBNRNCNWHE-UHFFFAOYSA-N 0.000 description 2
- JDVYDHPSYVFZSB-UHFFFAOYSA-N 6-[bis(2-methylpropyl)amino]-2-chloro-4-phenylpyridine-3-carbonitrile Chemical compound ClC1=NC(N(CC(C)C)CC(C)C)=CC(C=2C=CC=CC=2)=C1C#N JDVYDHPSYVFZSB-UHFFFAOYSA-N 0.000 description 2
- IFHWFGSBSBWBQU-UHFFFAOYSA-N 6-n,6-n-diethyl-4-phenyl-2h-pyrazolo[3,4-b]pyridine-3,6-diamine Chemical compound C=12C(N)=NNC2=NC(N(CC)CC)=CC=1C1=CC=CC=C1 IFHWFGSBSBWBQU-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000011837 pasties Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WCTJXHJLETVGMH-UHFFFAOYSA-N 1-(3-amino-4-phenyl-2h-pyrazolo[3,4-b]pyridin-6-yl)piperidin-3-ol Chemical compound C=12C(N)=NNC2=NC(N2CC(O)CCC2)=CC=1C1=CC=CC=C1 WCTJXHJLETVGMH-UHFFFAOYSA-N 0.000 description 1
- IYYBSCDHSUXBAR-UHFFFAOYSA-N 1-benzyl-6-morpholin-4-yl-4-phenylpyrazolo[3,4-b]pyridin-3-amine Chemical compound C12=NC(N3CCOCC3)=CC(C=3C=CC=CC=3)=C2C(N)=NN1CC1=CC=CC=C1 IYYBSCDHSUXBAR-UHFFFAOYSA-N 0.000 description 1
- OURNVKBSPQHZIT-UHFFFAOYSA-N 1-methyl-6-morpholin-4-yl-4-phenylpyrazolo[3,4-b]pyridin-3-amine Chemical compound N1=C2N(C)N=C(N)C2=C(C=2C=CC=CC=2)C=C1N1CCOCC1 OURNVKBSPQHZIT-UHFFFAOYSA-N 0.000 description 1
- RWQXKACXTVJKGP-UHFFFAOYSA-N 2,6-dibromo-4-phenylpyridine-3-carbonitrile Chemical compound BrC1=NC(Br)=CC(C=2C=CC=CC=2)=C1C#N RWQXKACXTVJKGP-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- JWIQOQGLGULJEZ-UHFFFAOYSA-N 2-chloro-4-(3-chlorophenyl)-6-morpholin-4-ylpyridine-3-carbonitrile Chemical compound ClC1=CC=CC(C=2C(=C(Cl)N=C(C=2)N2CCOCC2)C#N)=C1 JWIQOQGLGULJEZ-UHFFFAOYSA-N 0.000 description 1
- JSZOZKKQOCUJCV-UHFFFAOYSA-N 2-chloro-4-(4-methoxyphenyl)-6-morpholin-4-ylpyridine-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=CC(N2CCOCC2)=NC(Cl)=C1C#N JSZOZKKQOCUJCV-UHFFFAOYSA-N 0.000 description 1
- VIVIFQIHBDSOGV-UHFFFAOYSA-N 2-chloro-4-(4-methoxyphenyl)-6-piperidin-1-ylpyridine-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=CC(N2CCCCC2)=NC(Cl)=C1C#N VIVIFQIHBDSOGV-UHFFFAOYSA-N 0.000 description 1
- ABZFTEWABAWRAC-UHFFFAOYSA-N 2-chloro-4-phenyl-6-(4-phenylpiperidin-1-yl)pyridine-3-carbonitrile Chemical compound N#CC=1C(Cl)=NC(N2CCC(CC2)C=2C=CC=CC=2)=CC=1C1=CC=CC=C1 ABZFTEWABAWRAC-UHFFFAOYSA-N 0.000 description 1
- LUAQTQAFUORQHV-UHFFFAOYSA-N 2h-pyrazolo[3,4-b]pyridin-3-amine Chemical class C1=CC=C2C(N)=NNC2=N1 LUAQTQAFUORQHV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MVRZCIKSGQEKHB-UHFFFAOYSA-N 4-(2-fluorophenyl)-6-morpholin-4-yl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C=12C(N)=NNC2=NC(N2CCOCC2)=CC=1C1=CC=CC=C1F MVRZCIKSGQEKHB-UHFFFAOYSA-N 0.000 description 1
- LZRIOQVSRUAGBY-UHFFFAOYSA-N 4-(3-chlorophenyl)-6-morpholin-4-yl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C=12C(N)=NNC2=NC(N2CCOCC2)=CC=1C1=CC=CC(Cl)=C1 LZRIOQVSRUAGBY-UHFFFAOYSA-N 0.000 description 1
- GIODOUJHYFGQRB-UHFFFAOYSA-N 4-(4-chlorophenyl)-6-morpholin-4-yl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C=12C(N)=NNC2=NC(N2CCOCC2)=CC=1C1=CC=C(Cl)C=C1 GIODOUJHYFGQRB-UHFFFAOYSA-N 0.000 description 1
- URVNYGDVBTZXDL-UHFFFAOYSA-N 4-(4-fluorophenyl)-6-morpholin-4-yl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C=12C(N)=NNC2=NC(N2CCOCC2)=CC=1C1=CC=C(F)C=C1 URVNYGDVBTZXDL-UHFFFAOYSA-N 0.000 description 1
- DLVBLKNHFRZQJK-UHFFFAOYSA-N 4-(4-methoxyphenyl)-6-morpholin-4-yl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1=CC(OC)=CC=C1C1=CC(N2CCOCC2)=NC2=C1C(N)=NN2 DLVBLKNHFRZQJK-UHFFFAOYSA-N 0.000 description 1
- XXQMPMTXYTVIIM-UHFFFAOYSA-N 4-(4-methoxyphenyl)-6-piperidin-1-yl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1=CC(OC)=CC=C1C1=CC(N2CCCCC2)=NC2=C1C(N)=NN2 XXQMPMTXYTVIIM-UHFFFAOYSA-N 0.000 description 1
- ZBDCERWOULPXBC-UHFFFAOYSA-N 4-phenyl-2h-pyrazolo[3,4-b]pyridine-3,6-diamine Chemical compound C12=C(N)NN=C2N=C(N)C=C1C1=CC=CC=C1 ZBDCERWOULPXBC-UHFFFAOYSA-N 0.000 description 1
- AGUFHXKIHVAERU-UHFFFAOYSA-N 4-phenyl-6-(4-phenylpiperazin-1-yl)-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C=12C(N)=NNC2=NC(N2CCN(CC2)C=2C=CC=CC=2)=CC=1C1=CC=CC=C1 AGUFHXKIHVAERU-UHFFFAOYSA-N 0.000 description 1
- XJEBRGHZFNTLEP-UHFFFAOYSA-N 4-phenyl-6-(4-phenylpiperidin-1-yl)-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C=12C(N)=NNC2=NC(N2CCC(CC2)C=2C=CC=CC=2)=CC=1C1=CC=CC=C1 XJEBRGHZFNTLEP-UHFFFAOYSA-N 0.000 description 1
- AYWMZHNVRRRWKI-UHFFFAOYSA-N 4-phenyl-6-n,6-n-dipropyl-2h-pyrazolo[3,4-b]pyridine-3,6-diamine Chemical compound C=12C(N)=NNC2=NC(N(CCC)CCC)=CC=1C1=CC=CC=C1 AYWMZHNVRRRWKI-UHFFFAOYSA-N 0.000 description 1
- QDJAFEAMVFTNMG-UHFFFAOYSA-N 4-phenyl-6-n-propan-2-yl-2h-pyrazolo[3,4-b]pyridine-3,6-diamine Chemical compound C=12C(N)=NNC2=NC(NC(C)C)=CC=1C1=CC=CC=C1 QDJAFEAMVFTNMG-UHFFFAOYSA-N 0.000 description 1
- JGRHSRZHAULPRN-UHFFFAOYSA-N 4-phenyl-6-piperazin-1-yl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C=12C(N)=NNC2=NC(N2CCNCC2)=CC=1C1=CC=CC=C1 JGRHSRZHAULPRN-UHFFFAOYSA-N 0.000 description 1
- CWFLYTMZJHCJQH-UHFFFAOYSA-N 4-phenyl-6-pyrrolidin-1-yl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C=12C(N)=NNC2=NC(N2CCCC2)=CC=1C1=CC=CC=C1 CWFLYTMZJHCJQH-UHFFFAOYSA-N 0.000 description 1
- UKKIWKUWKHIFTK-UHFFFAOYSA-N 6-(2,6-dimethylmorpholin-4-yl)-4-phenyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1C(C)OC(C)CN1C1=CC(C=2C=CC=CC=2)=C(C(N)=NN2)C2=N1 UKKIWKUWKHIFTK-UHFFFAOYSA-N 0.000 description 1
- RHOLOTNJNZSXFM-UHFFFAOYSA-N 6-(2,6-dimethylpiperidin-1-yl)-4-phenyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound CC1CCCC(C)N1C1=CC(C=2C=CC=CC=2)=C(C(N)=NN2)C2=N1 RHOLOTNJNZSXFM-UHFFFAOYSA-N 0.000 description 1
- DXHRIUVZNYRYHI-UHFFFAOYSA-N 6-(2,6-dimethylthiomorpholin-4-yl)-4-phenyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1C(C)SC(C)CN1C1=CC(C=2C=CC=CC=2)=C(C(N)=NN2)C2=N1 DXHRIUVZNYRYHI-UHFFFAOYSA-N 0.000 description 1
- HHRGXTJIZWXOKQ-UHFFFAOYSA-N 6-(2-methylmorpholin-4-yl)-4-phenyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1COC(C)CN1C1=CC(C=2C=CC=CC=2)=C(C(N)=NN2)C2=N1 HHRGXTJIZWXOKQ-UHFFFAOYSA-N 0.000 description 1
- BXYWDRVUHUELKN-UHFFFAOYSA-N 6-(2-methylpiperidin-1-yl)-4-phenyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound CC1CCCCN1C1=CC(C=2C=CC=CC=2)=C(C(N)=NN2)C2=N1 BXYWDRVUHUELKN-UHFFFAOYSA-N 0.000 description 1
- DWFNQUGTGWTIMH-UHFFFAOYSA-N 6-(3-methylpiperidin-1-yl)-4-phenyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1C(C)CCCN1C1=CC(C=2C=CC=CC=2)=C(C(N)=NN2)C2=N1 DWFNQUGTGWTIMH-UHFFFAOYSA-N 0.000 description 1
- CVJYLAANOAJTSD-UHFFFAOYSA-N 6-(4-benzylpiperazin-1-yl)-4-phenyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C=12C(N)=NNC2=NC(N2CCN(CC=3C=CC=CC=3)CC2)=CC=1C1=CC=CC=C1 CVJYLAANOAJTSD-UHFFFAOYSA-N 0.000 description 1
- CLOUZDXBDRWUCF-UHFFFAOYSA-N 6-(4-benzylpiperidin-1-yl)-4-phenyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C=12C(N)=NNC2=NC(N2CCC(CC=3C=CC=CC=3)CC2)=CC=1C1=CC=CC=C1 CLOUZDXBDRWUCF-UHFFFAOYSA-N 0.000 description 1
- WDKJGVVDHXNWNF-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)-4-phenyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1CN(C)CCN1C1=CC(C=2C=CC=CC=2)=C(C(N)=NN2)C2=N1 WDKJGVVDHXNWNF-UHFFFAOYSA-N 0.000 description 1
- BGCDEYKVQIHZNV-UHFFFAOYSA-N 6-(4-methylpiperidin-1-yl)-4-phenyl-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1CC(C)CCN1C1=CC(C=2C=CC=CC=2)=C(C(N)=NN2)C2=N1 BGCDEYKVQIHZNV-UHFFFAOYSA-N 0.000 description 1
- PDSCQNWPHWQFLE-UHFFFAOYSA-N 6-(azepan-1-yl)-2-chloro-4-(4-fluorophenyl)pyridine-3-carbonitrile Chemical compound C1=CC(F)=CC=C1C1=CC(N2CCCCCC2)=NC(Cl)=C1C#N PDSCQNWPHWQFLE-UHFFFAOYSA-N 0.000 description 1
- HGUUFTJZJRKURG-UHFFFAOYSA-N 6-(azepan-1-yl)-4-(4-methylphenyl)-2h-pyrazolo[3,4-b]pyridin-3-amine Chemical compound C1=CC(C)=CC=C1C1=CC(N2CCCCCC2)=NC2=NNC(N)=C12 HGUUFTJZJRKURG-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- OTJIOIFRUCWONM-UHFFFAOYSA-N 6-morpholin-4-yl-2-phenoxy-4-phenylpyridine-3-carbonitrile Chemical compound O1CCN(CC1)C1=NC(=C(C#N)C(=C1)C1=CC=CC=C1)OC1=CC=CC=C1 OTJIOIFRUCWONM-UHFFFAOYSA-N 0.000 description 1
- VSGXASDNNXEXGI-UHFFFAOYSA-N 6-n,6-n-bis(2-methylpropyl)-4-phenyl-2h-pyrazolo[3,4-b]pyridine-3,6-diamine Chemical compound C=12C(N)=NNC2=NC(N(CC(C)C)CC(C)C)=CC=1C1=CC=CC=C1 VSGXASDNNXEXGI-UHFFFAOYSA-N 0.000 description 1
- IFUIOLGBCRGZLJ-UHFFFAOYSA-N 6-n,6-n-dibutyl-4-phenyl-2h-pyrazolo[3,4-b]pyridine-3,6-diamine Chemical compound C=12C(N)=NNC2=NC(N(CCCC)CCCC)=CC=1C1=CC=CC=C1 IFUIOLGBCRGZLJ-UHFFFAOYSA-N 0.000 description 1
- FNQJXDRONVFMPZ-UHFFFAOYSA-N 6-n,6-n-dimethyl-4-phenyl-2h-pyrazolo[3,4-b]pyridine-3,6-diamine Chemical compound C=12C(N)=NNC2=NC(N(C)C)=CC=1C1=CC=CC=C1 FNQJXDRONVFMPZ-UHFFFAOYSA-N 0.000 description 1
- BDEZVJWFZBIGOD-UHFFFAOYSA-N 6-n-(3-methylbutyl)-4-phenyl-2h-pyrazolo[3,4-b]pyridine-3,6-diamine Chemical compound C=12C(N)=NNC2=NC(NCCC(C)C)=CC=1C1=CC=CC=C1 BDEZVJWFZBIGOD-UHFFFAOYSA-N 0.000 description 1
- DTVZDLPECNHRPA-UHFFFAOYSA-N 6-n-benzyl-4-phenyl-2h-pyrazolo[3,4-b]pyridine-3,6-diamine Chemical compound C=1C(C=2C=CC=CC=2)=C2C(N)=NNC2=NC=1NCC1=CC=CC=C1 DTVZDLPECNHRPA-UHFFFAOYSA-N 0.000 description 1
- OYKBGMULWHIVGU-UHFFFAOYSA-N 6-n-benzyl-6-n-methyl-4-phenyl-2h-pyrazolo[3,4-b]pyridine-3,6-diamine Chemical compound C=1C(C=2C=CC=CC=2)=C2C(N)=NNC2=NC=1N(C)CC1=CC=CC=C1 OYKBGMULWHIVGU-UHFFFAOYSA-N 0.000 description 1
- NZYGBIBZQWTQHR-UHFFFAOYSA-N 6-n-cyclohexyl-6-n-methyl-4-phenyl-2h-pyrazolo[3,4-b]pyridine-3,6-diamine Chemical compound C=1C(C=2C=CC=CC=2)=C2C(N)=NNC2=NC=1N(C)C1CCCCC1 NZYGBIBZQWTQHR-UHFFFAOYSA-N 0.000 description 1
- NOBCRVQNQCFBQS-UHFFFAOYSA-N 6-n-ethyl-4-phenyl-2h-pyrazolo[3,4-b]pyridine-3,6-diamine Chemical compound C=12C(N)=NNC2=NC(NCC)=CC=1C1=CC=CC=C1 NOBCRVQNQCFBQS-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ISGOVOJOCCTIJP-UHFFFAOYSA-N C1CCCN(CC1)C2(C=CC(=C(N2)Cl)C#N)C3=CC=C(C=C3)F Chemical compound C1CCCN(CC1)C2(C=CC(=C(N2)Cl)C#N)C3=CC=C(C=C3)F ISGOVOJOCCTIJP-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- GKKZMYDNDDMXSE-UHFFFAOYSA-N Ethyl 3-oxo-3-phenylpropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=CC=C1 GKKZMYDNDDMXSE-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- RFRGMHDZPGNMLQ-UHFFFAOYSA-N [1-(3-amino-4-phenyl-2h-pyrazolo[3,4-b]pyridin-6-yl)piperidin-3-yl]methanol Chemical compound C=12C(N)=NNC2=NC(N2CC(CO)CCC2)=CC=1C1=CC=CC=C1 RFRGMHDZPGNMLQ-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- NHOWLEZFTHYCTP-UHFFFAOYSA-N benzylhydrazine Chemical compound NNCC1=CC=CC=C1 NHOWLEZFTHYCTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- NESLWCLHZZISNB-UHFFFAOYSA-M sodium phenolate Chemical compound [Na+].[O-]C1=CC=CC=C1 NESLWCLHZZISNB-UHFFFAOYSA-M 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
I tysk off.skrift 2.232.038 er beskrevet 3-amino-lH-pyrazolo[3,4-b]pyridiner, som representerer verdifulle mellom-produkter for fremstilling av farvestoffer, særlig azo-farvestoffer.
Det er nu funnet at de nye lH-pyrazolo[3,4-b]pyridiner
med den generelle formel
hvor
betyr en etylamino-, isopropylamino-, isoamylamino-, benzylamino-, dimetylamino-, dietylamino-, dipropylamino-, dibutylamino-, diisobutylamino-, N-metyl-cykloheksylamino-, N-metyl-benzylamino-, dialiylamino-, pyrrolidino-, heksametylenimino-, piperidino-, metylpiperidino-, hydroksymetylpiperidino-, hydroksypiperidino-, fenylpiperidino-, benzylpiperidino-, dimetylpiperidino-, morfolino-, metylmorfolino-, dimetyl-morfolino-, piperazino-, N-metylpiperazino-, N-fenyl-piperazino-, N-benzyl-piperazino-, tiomorfolino-, dimetyl-tiomorfolino-, 1-oksydo-tiomorfolino-, metyl-l-oksydo-tiomorfolino-, 1,1-dioksydo-tiomorfolino-, 1,2,5,6-tetrahydro-pyridino-, 1,2,3,4-tetrahydroisokinolino-, indolino- eller 3,6-etylen-heksametyleniminogruppe,
R2 betyr et hydrogenatom, en metyl- eller benzylgruppe, og
R^ betyr et hydrogen-, fluor- eller kloratom, eller en metyl-eller metoksygruppe,
og deres fysiologisk forlikelige salter med uorganiske eller organiske syrer, oppviser verdifulle farmakologiske egenskaper, ved siden av en antiflogistisk, særlig anti-trombotisk virkning.
Særlig foretrukne forbindelser er de hvor R^ betyr
en dietylamino-, pyrrolidino-, piperidino-, 3-metyl-piperidino-, heksametylenimino-, morfoiino- eller tiomorfolinogruppe,
R2 betyr et hydrogenatom, og R^ betyr et hydrogen-, fluor- eller kloratom, eller en metoksygruppe.
De nye forbindelser med den generelle formel I fremstilles i henhold til oppfinnelsen som felger:
Omsetning av et pyridin med den generelle formel
hvor
R er som ovenfor angitt,
R^<1> betyr en med en acylgruppe i 4-stilling beskyttet piperazinogruppe og de for R^ innledningsvis angitte betydninger, og
X betyr en nukleofil, utskiftbar gruppe,
med et hydrazin med den generelle formel
hvor
R^ er som innledningsvis angitt.
Som såkalt "utgående" gruppe kan X f.eks. bety et
klor- eller bromatom eller en aryloksyrest så som en fenoksygruppe.
Omsetningen utføres hensiktsmessig i et oppløsningsmiddel så som dimetylformamid, dimetylsulfoksyd, vann, etylenglykol, propylenglykol, 2-etoksyetanol eller i et overskudd av det anvendte hydrazin med den generelle formel III, eventuelt i nærvær av en base så som natriumkarbonat, pyridin eller i et overskudd av det anvendte hydrazin, ved forhøyet temperatur, f.eks. ved temperaturer mellom 70 og 180°C, fortrinnsvis ved temperaturer mellom 100 og 150°C. Omsetningen kan imidlertid også utføres uten oppløsningsmiddel.
De erholdte forbindelser med den generelle formel I kan eventuelt overføres med uorganiske eller organiske syrer til sine fysiologisk forlikelige syreaddisjonssalter. Egnede syrer er f.eks. saltsyre, bromhydrogensyre, svovelsyre, fosforsyre, melkesyre, sitronsyre, vinsyre, maleinsyre eller fumarsyre.
De som utgangsstoffer anvendte forbindelser med den generelle formel II er nye og kan fremstilles ved i og for seg kjente metoder fra de tilsvarende 2,6-dihalogenpyridiner ved 1 j omsetning med et tilsvarende amin med den generelle formel H-R-^' ved forhøyet temperatur, f.eks. ved det anvendte oppløsningsmiddels koketemperatur.
Som nevnt innledningsvis er de nye forbindelser med den generelle formel I i besittelse av verdifulle farmakologiske egenskaper, ved siden av en antiflogistisk, særlig antitrombotisk virkning.
Som eksempler ble forbindelsene
A = 3-amino-6-morfolino-4-fenyl-lH-pyrazolo[3,4-b]pyridin,
B = 3-amino-4-feny1-6-tiomorfolino-lH-pyrazolo[3,4-b]pyridin,
C = 3-amino-4-fenyl-6-piperidino-lH-pyrazolo[3,4-b]pyridin,
D = 3-amino-6-(3-metylpiperidino)-4-fenyl-lH-pyrazolo[3,4-b]-pyridin,
E = 3-amino-6-heksametylenimino-4-fenyl-lH-pyrazolo[3,4-b]pyridin,
F = 3-amino-6-dietylamino-4-fenyl-lH-pyrazolo[3,4-b]pyridin,
G = 3-amino-4-(4<1->metoksyfenyl)-6-piperidino-lH-pyrazolo[3,4-b]-pyridin, og
H = 3-amino-4-(4'-fluorfenyl)-6-heksametylenimino-lH-pyrazolo-[3,4-b]pyridin
til sammenligning med
I = 3,6-diamino-4-fenyl-lH-pyrazolo[3,4-b]pyridin (DE OS 2.232.038)
undersøkt med hensyn til sine biologiske virkninger:
1. Bestemme lse av trombocyttaggregatdannelsen ifølge
Born og Cross ( J. Physiol. 170. 397 ( 1964)): Trombocyttaggregatdannelsen ble målt i blodplaterikt plasma fra sunne forsøkspersoner. Herunder ble forløpet av for-andringen av den optiske tetthet efter tilsetning av handelsvanlig kollagen fra firma Hormonchemie, Miinchen, som inneholder 1 mg kollagenfibriller pr. ml, målt fotometrisk og registrert. På grunnlag av tetthetskurvens stigningsvinkel ble aggregatdannelses-hastighete<n> (<v>maks) beregnet. Det punkt på kurven hvor det forelå den største lysgjennomgang, tjente til beregning av den optiske tetthet (0.D.).
Kollagendosene ble valgt lavest mulig, men imidlertid slik at de ga en irrsversibel aggregatdanneIse. For maksimal aggregatutløsning settes ca. 0,01 ml av kollagenoppløsningen til 1 ml blodplaterikt plasma.
Prøveforbindelsene ble før aggregatutløsningen inkubert med plasmaet i 10 minutter ved 37°C. Forbindelsene ble oppløst med noe saltsyre eller dimetylformamid og fortynnet til den ønskede sluttkonsentrasjon med destillert vann.
Man bestemte ED^Q, dvs. den dose som bevirket en
50%ig hemning av aggregatdannelsen sammenlignet med kontrollen:
2. Akutt toksisitet
Den akutte toksisitet av prøveforbindelsene ble bestemt orienterende på hvite mus (observasjonstid: 14 dager) efter oral administrering av en engangsdose:
De nye forbindelser med den generelle formel I og deres fysiologisk forlikelige salter med uorganiske og organiske syrer er således særlig egnet til forebyggelse av arteriellé trombo-embolier og arteriellé tilstoppningslidelser, og kan for farmasøytisk anvendelse innføres i de vanlige farmasøytiske til-beredelsesformer så som tabletter, dragéer, kapsler, stikkpiller, ampuller og oppløsninger, eventuelt i kombinasjon med andre aktive stoffer. Enkeltdosen er for voksne hensiktsmessig 50-200 mg, fortrinnsvis 120-170 mg, 3 til 4 ganger daglig.
De følgende eksempler skal tjene til å illustrere oppfinnelsen ytterligere:
Forbemerkning:
Ved smeltepunktangivelsene er det tale om ukorrigerte smeltepunkter.
Eksempler på fremstilling av utgangsforbindelsene:
Eksempel A
2, 6- dihydroksy- 4- fenyl- nikotinonitril
84 g (1 mol) cyanacetamid og 192 g (1 mol) benzoyl-eddiksyre-etylester oppløses i 200 ml absolutt etanol under oppvarmning. Til den erholdte oppløsning settes derefter langsomt dråpevis under videre oppvarmning en oppløsning av 56 g (1 mol) kaliumhydroksyd i 200 ml absolutt etanol i løpet av ca. 2 timer. Den erholdte blanding oppvarmes derefter i ca. 20 timer under tilbakeløpskjøling, hvorved kaliumsaltet av 2,6-dihydroksy-4-fenylnikotinonitril gradvis utfelles. Efter avkjøling avsuges det og oppløses i 2-3 liter varmt vann. Ved surgjøring med konsentrert saltsyre utfelles derefter 2,6-dihydroksy-4-fenyl-nikotinonitril som elfenbensfarvet krystallinsk bunnfall. Efter avkjøling avsuges dette, vaskes med vann og litt aceton og tørres. Utbytte: 89 g (42% av det teoretiske), sm.p.: ca. 280°C (spaltn.).
Eksempel B
2, 6- diklor- 4- fenyl- nikotinonitril
42,4 g (0,2 mol) 2,6-dihydroksy-4-fenyl-nikotinonitril oppvarmes sammen med 300 ml fosforoksyklorid i et glass-trykkar under risting i 6 timer til ca. 180°C. Efter avkjøling helles reaksjonsblandingen porsjonsvis under omrøring i en blanding av
is og vann (ca. 3 liter). Det utskilte bunnfall avsuges, vaskes med vann og tørres. Utbytte: 47,4 g (95% av det teoretiske).
Det erholdte reaksjonsprodukt oppløses i kloroform (frafiltréring av et lite residuum) og renses over en kort silikagelkolonne med kloroform som utviklingsmiddel. Efter samling og inndampning av kloroformfraksjonene får man 2,6-diklor-4-fenyl-nikotinonitril i form av nesten farveløse krystaller.
Utbytte: 37,5 g (75% av det teoretiske); sm.p. 167-169°C.
På analog måte ble også fremstilt:
2, 6- dibrom- 4- fenyl- nikotinonitril
ved omsetning av 2,6-dihydroksy-4-fenyl-nikotinonitril med fosforoksybromid resp. med fosfortribromid og trietylamin, men imidlertid uten trykk.
Sm.p.: 186-188°C (etylacetat).
Eksempel C
2- klor- 6- morfolino- 4- fenyl- nikotinonitril
En suspensjon av 24,9 g (0,1 mol) 2,6-diklor-4-fenyl-nikotinonitril i 400 ml etanol tilsettes langsomt 17,4 g (0,2 mol) morfolin og oppvarmes derefter i ca. 2 timer under tilbakeløps-kjøling. Allerede under kokningen, men særlig under avkjølingen av reaksjonsblandingen (eventuelt avkjøling med isvann) utskilles reaksjonsproduktet som farveløs, krystallinsk bunnfall. Det avsuges, vaskes meget grundig med vann og tørres.
Utbytte: 25,8 g (86% av det teoretiske); sm.p. 198-200°C.
Analogt med eksempel C ble også de følgende utgangs-forbindelser fremstilt:
6-etylamino-2-klor-4-fenyl-nikotinonitril,
Sm.p.: 215-218°C.
2-klor-6-isopropylamino-4-fenyl-nikotinonitril,
Sm.p.: 147-149°C.
2-klor-6-isoamylamino-4-fenyl-nikotinonitril,
Sm.p.: 167-169°C.
2-klor-6-dimetylamino-4-fenyl-nikotinonitril,
Sm.p.: 168-170°C.
2-klor-6-dietylamino-4-fenyl-nikotinonitril,
Sm.p.: 100-106°C (isomerblanding).
2-klor-6-dibutylamino-4-fenyl-nikotinonitril,
Sm.p.: 111-113°C.
6-benzylamino-2-klor-4-fenyl-nikotinonitril,
Sm.p.: 167-169°C.
2-klor-6-(N-metyl-benzylamino)-4-fenyl-nikotinonitril, Sm.p.: 161-163°C.
2-klor-6-(N-metyl-cykloheksylamino)-4-fenyl-nikotinonitril, Sm.p.: 176-178°C.
2-klor-6-diallylamino-4-fenyl-nikotinonitril,
Sm.p.: 86-88°C.
2-klor-4-fenyl-6-pyrrolidino-nikotinonitril,
Sm.p.: 180-192°C.
2-klor-4-fenyl-6-piperidino-nikotinonitril,
Sm.p.: 173-176°C.
2-klor-4-fenyl-6-(1,2,5,6-tetrahydropyridino)-nikotinonitril, Sm.p.: 174-176°C.
2-klor-6- (2-metylpiperidino)-4-fenyl-nikotinonitril,
Sm.p.: 103-106°C.
2-klor-6-(3-metylpiperidino)-4-fenyl-nikotinonitril,
Sm.p.: 108-110°C.
2-klor-6-(4-metylpiperidino)-4-fenyl-nikotinonitril,
Sm.p.: 130-132°C.
2-klor-6-(2,6-dimetylpiperidino)-4-fenyl-nikotinonitril, Sm.p.: 120-123°C.
6- (4-benzylpiperidino)-2-klor-4-fenyl-nikotinonitril, Sm.p.: 141-143°C.
2-klor-4-fenyl-6-(4-fenylpiperidino)-nikotinonitril,
Sm.p.: 183-185°C.
2-klor-6-(3-hydroksymetylpiperidino)-4-fenyl-nikotinonitril, Sm.p.: 150-153°C.
2-klor-6- (3-hydroksypiperidino)-4-fenyl-nikotinonitril, Sm.p.: 183-185°C.
2-klor-6-heksametylenimino-4-fenyl-nikotinonitril,
Sm.p.: 136-138°C.
2-klor-6-(2-metylmorfolino)-4-fenyl-nikotinonitril,
Sm.p-: 173-176°C.
2-klor-6-(2,6-dimetylmorfolino)-4-fenyl-nikotinonitril,
Sm.p.: 165-178°C (isomerblanding)
2-klor-4-fenyl-6-tiomorfolino-nikotinonitril,
Sm.p.: 165-167°C.
2-klor-6-(2,6-dimetyltiomorfolino)-4-fenyl-nikotinonitril, Sm.p.: 144-147°C.
2-klor-6-(1-oksydo-tiomorfolino)-4-fenyl-nikotinonitril,
Sm.p.: 222-224°C.
2-klor-6-(2-metyl-l-oksydo-tiomorfolino)-4-fenyl-nikotinonitril, Sm.p.: 215-216°C.
2-klor-6- (1,1-dioksydo-tiomorfolino)-4-fenyl-nikotinonitril, Sm.p.: 240-242°C.
2-klor-6-(N-formylpiperazino)-4-fenyl-nikotinonitril,
Sm.p-: 180-182°C
2-klor-6-(N-metylpiperazino)-4-fenyl-nikotinonitril,
Sm.p.: 180-182°C.
2-klor-6- (N-benzylpiperazino)-4-fenyl-nikotinonitril,
Sm.p.: 165-167°C.
2-klor-6-(N-fenylpiperazino)-4-fenyl-nikotinonitril,
Sm.p.: 232-234°C.
2-klor-4-fenyl-6-(1,2,3,4-tetrahydroisokinolino)-nikotinonitril, Sm.p.: 159-161°C.
2-klor-6-indolino-4-fenyl-nikotinonitril,
Sm.p.: 213-215°C.
6-(3,6-etylen-heksametylenimino)-2-klor-4-fenyl-nikotinonitril, Sm.p.: 136-138°C.
2-brom-6-morfolino-4-fenyl-nikotinonitril,
Sm.p.: 198-200°C.
2-klor-6-dipropylamino-4-fenyl-nikotinonitril,
Sm.p. : 120-122°C
2-klor-6-diisobutylamino-4-fenyl-nikotinonitril,
Sm.p.: 100-102°C.
2-klor-4-(p-metoksyfenyl)-6-piperidino-nikotinonitril,
Sm.p.: 189-190°C,
2-klor-4-(p-metoksyfenyl)-6-morfolino-nikotinonitril,
Sm.p.: 215-217°C.
2-klor-4-(p-fluorfenyl)-6-morfolino-nikotinonitril,
Sm.p.: 225-227°C.
2-klor-4-(o-fluorfenyl)-6-morfolino-nikotinonitril,
Sm.p.: 188-190°C.
2-klor-4-(p-klorfeny1)-6-morfolino-nikotinonitril,
Sm.p.: 250-252°C.
2-klor-4-(m-klorfenyl)-6-morfolino-nikotinonitril,
Sm.p.: 189-191°C.
2-klor-6-heksametylenimino-4-(p-rolyl)-nikotinonitril,
Sm.p.: 161-163°C.
2- klor-6-(p-fluorfenyl)-6-heksametylenimino-nikotinonitril,
Sm.p.: 160-162°C.
Eksempler på fremstilling av sluttproduktene:
E ksempel 1
3- amino- 6- morfolino- 4- feny1- lH- pyrazolo[ 3, 4- b] pyridin
15,0 g (0,05 mol) 2-klor-6-morfolino-4-fenyl-nikotinonitril (sm.p.: 198-200°C) oppvarmes med 20 ml hydrazinhydrat (80%ig) i 100 ml etylenglykol 3 timer til 130°C. Den erholdte oppløsning felles i ca. 1 liter vann, hvorved reaksjonsproduktet utskilles som et nesten farveløst bunnfall. Det avsuges, vaskes med vann og felles straks påny en gang fra ca. 700 ml 0,1N saltsyre ved hjelp av konsentrert ammoniakk. Efter avsugning, vasking og tørring utgjør utbyttet 13,7 g (93% av det teoretiske). Det således erholdte 3-amino-6-morfolino-4-fenyl-lH-pyrazolo[3,4-b]pyridin er praktisk talt rent og smelter ved 178-130°C.
Sm.p.: 180-182°C (fra etanol).
C16H17m50 1295,3)
Beregnet: C 65,07, H 5,80, N 23,71
Funnet: 65,20, 6,10, 23,80
Hydrokloridet av 3-amino-6-morfol:no-4-fenyl-lH-pyrazolo-[3,4-b]pyridin oppnås ved oppløsning i ca. 2N saltsyre under
oppvarmning og påfølgende utkrystallisering.
Sm.p.: 263-265°C.
Eksempel 2
3- amino- 6- morfolino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
3,4 g (0,01 mol) 2-brom-6-morfolino-4-fenyl-nikotinonitril (sm.p.: 198-200°C) oppvarmes med 5 ml hydrazinhydrat (80%ig) i 20 ml etylenglykol i 3 timer til ca. 130°C. Efter opparbeidelse og rensning analogt med eksempel 1 smelter reaksjonsproduktet ved 180-182°C.
Utbytte: 2,3 g (78% av det teoretiske).
Eksempel 3
3- amino- 6- morfolino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
3,6 g (0,01 mol) 6-morfolino-2-fenoksy-4-fenyl-nikotinonitril (sm.p.: 150-153°C, erholdt fra 2-klor-6-morfolino-4-fenyl-nikotinonitril og natriumfenolat i fenol ved 3 timers oppvarmning til 140°C) oppvarmes med 5 ml hydrazinhydrat (80%ig) i 25 ml etylenglykol i 5 timer til ca. 150°C (tilbakeløpskjøling). Den erholdte oppløsning helles i ca. 400 ml vann, hvorved reaksjonsproduktet utfelles som nesten farveløst bunnfall. Efter en gangs omfeining fra 0,1N saltsyre med konsentrert ammoniakk er utbyttet 2,1 g (71% av det teoretiske).
Sm.p.: 180-182°C (fra metanol)
<C>16<H>17<N>5° (<2>95'3)
Beregnet: C 65,07, H 5,80, N 23,71
Funnet: 65,10 5,84 23,40
E ksempel 4
3- amino- 6- heksametylenimino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
3,1 g (0,01 mol) 2-klor-6-heksametylenimino-4-fenyl-nikotinonitril (sm.p.: 136-138°C) oppvarmes med 4 ml hydrazin-
hydrat (80%ig) i 20 ml 2-etoksyetanol i ca. 2 timer under tilbakeløps-kjøling og opparbeides derefter analogt med eksempel 1. Efter omfelning en gang fra 0,1N saltsyre med konsentrert ammoniakk er utbyttet 2,8 g (91% av det teoretiske). Den således erholdte forbindelse smelter ved 200-202°C.
Sm.p.: 201-203°C (fra etanol eller etylacetat)
<C>18H21<N>5 (<3>07,4)
Beregnet: C 70,33, H 6,89, N 22,78
Funnet: 70,10, 6,90, 22,80
Eksempel 5
3- amino- l- metyl- 6- merfolino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
3,0 g (0,01 mol) 2-klor-6-morfolino-4-feny1-nikotino-
nitril oppvarmes med 1,4 g (0,03 mol) metylhydrazin og 4 ml etylenglykol i 3 timer til 170°C (badtemperatur) under tilbakeløps-kjøling. Den erholdte oppløsning opptas i 50 ml vann, hvorved reaksjonsproduktet først utfelles som pastaaktig bunnfall. Det oppsluttes med vann og avsuges efter størkning, vaskes og tørres. Utbytte: 2,8 g (91% av det teoretiske).
Efter omkrystallisering eri gang fra metanol smelter 3-amino-l-metyl-6-morfolino-4-fenyl-lH-pyrazolo[3,4-b]pyridin ved 149-152°C.
<C>17H19<N>5<0> (<3>09,4)
Beregnet: C 65,00, H 6,19, N 22,64
Funnet: 65,00, 6,25, 22,72
E ksempel 6
3- amino- 1- benzyl- 6- morfolino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
3,0 g (0,01 mol) 2-klor-6-morfolino-4-fenyl-nikotino-
nitril oppvarmes med 3,7 g (0,03 mol) benzylhydrazin i 30 ml etylenglykol i 5 timer til ca. 130°C under tilbakeløpskjøling.
Ved opptagelse av den erholdte oppløsning i 100 ml vann utfelles reaksjonsproduktet som et pastaaktig bunnfall. Det omkrystalliseres straks en gang fra metanol.
Utbytte: 2,2 g (57% av det teoretiske),
Sm.p.: 147-150°C (fra etylacetat)
<C>23H23<N>5<0> (<3>85,5)
Beregnet: C 71,67, H 6,01, N 18,17
Funnet: 71,60, 6,28, 17,90
E ksempel 7
6- etylamino- 3- amino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 6-etylamino-2-klor-4- fenyl-nikotinonitril (sm.p.: 215-218°C) og hydrazinhydrat. •
Sm.p.: 208-210°C..
Eksempel 8
3- amino- 6- isopropylamino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-isopropylamino-4-fenyl-nikotinonitril (sm.p.: 147-149°C) og hydrazinhydrat. Sm.p.: 126-128°C.
Eksempel 9
3- amino- 6- isoamylamino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-isoamylamino-4-fenyl-nikotinonitril (sm.p.: 167-169°C) og hydrazinhydrat. Sm.p.: 130-132°C (metanol-vann).
Eksempel 10
3- amino- 6- dimetylamino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-dimetylamino-4- fenyl-nikotinonitril (sm.p.: 168-170°C) og hydrazinhydrat. Sm.p.: 239-241°C.
Eksempel 11
3- amino- 6- dietylamino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-dietylamino-4-fenylnikotinonitril (sm.p.: 100-106°C, isomerblanding) og hydrazinhydrat.
Sm.p.: 175-177°C.
Eksempel 12
3- amino- 6- dibutylamino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-dibutylamino-4-fenyl-nikotinonitril (sm.p.: 111-113°C) og hydrazinhydrat. Sm.p.: 131-133°C (metanol).
Eksempel 13
3- amino- 6- benzylamino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 6-benzylamino-2-klor-4- fenyl-nikotinonitril (sm.p.: 167-169°C) og hydrazinhydrat, sintring fra ca. 65~C.
Eksempel 14
3- amino- 6-( N- metyl- benzylamino)- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 frå 2-klor-6-(N-metyl-benzylamino) -4-fenyl-nikotinonitril (sm.p.: 161-163°C) og hydrazinhydrat.
Sm.p.: 208-210°C (isopropanol).
Eksempel 15
3- amino- 6-( N- metyl- cykloheksylamino)- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(N-metyl-cykloheksylamino)-4-fenyl-nikotinonitril (sm.p.: 176-178°C) og hydrazinhydrat.
Sm.p.: 107-109°C.
Eksempel 16
3- amino- 6- diallylamino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-diallylamino-4-fenylnikotinonitril (sm.p.: 86-88°C) og hydrazinhydrat.
Sm.p.: 150-151°C (metanol).
Eksempel 17
3- amino- 4- fenyl- 6- pyrrolidino- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-4-fenyl-6-pyrrolidino-nikotinonitril (sm.p.: 180-182°C) og hydrazinhydrat. Sm.p.: 252-255°C.
Eksempel 18
3- amino- 4- fenyl- 6- piperidino- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-4-fenyl-6-piperidino-nikotinonitril (sm.p.: 173-176°C) og hydrazinhydrat. Sm.p.: 196-199°C.
Eksempel 19
3- amino- 4- fenyl- 6-( 1, 2, 5, 6- tetrahydropyridino)- lH- pyrazolo[ 3, 4- b]-pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-4-fenyl-6-(1,2,5,6-tetrahydropyridino)-nikotinonitril (sm.p. 174-176°C)
og hydrazinhydrat.
Sm.p.: 174-177°C.
Eksempel 20
3- amino- 6-( 2- metylpiperidino)- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(2-metyl-piperidino) -4-fenyl-nikotinonitril (sm.p.: 103-106°C) og hydrazinhydrat.
Sm.p.: 163-165°C.
Eksempel 21
3- amino- 6-( 3- metylpiperidino)- 4- fenyl- lH- pyrazolo[ 3, 4- b1pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(3-metyl-piperidino) -4-fenyl-nikotinonitril (sm.p.: 108-110°C) og hydrazinhydrat i propylenglykol.
Sm.p.: 182-185°C.
Eksempel 22
3- amino- 6-( 4- metylpiperidino)- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(4-metyl-piperidino) -4-fenyl-nikotinonitril (sm.p.: 130-132°C) og hydrazinhydrat.
Sm.p. 206-208°C.
Eksempel 2 3
3- amino- 6-( 2, 6- dimetylpiperidino)- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(2,6-dimetylpiperidino)-4-fenyl-nikotinonitril (sm.p.: 120-123°C) og hydrazinhydrat.
Sm.p.: 210-212°C.
Eksempel 2 4
3- amino- 6-( 4- benzylpiperidino)- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 6-(4-benzylpiperidino)-2- klor-4-fenyl-nikotinonitril (sm.p.: 141-143°C) og hydrazinhydrat. Sm.p.: 182-185°C (etylacetat).
Eksempel 2 5
3- amino- 4- fenyl- 6- ( 4- fenylpiperidino)- lH- pyrazolo[ 3, 4- b] pyridin Fremstilt analogt med eksempel 1 fra 2-klor-4-fenyl-6-
(4-fenyl-piperidino)-nikotinonitril (sm.p.: 183-185°C) og hydrazinhydrat.
Sm.p.: 225-228°C.
Eksempel 2 6
3- amino- 6- ( 3- hydroksymetylpiperidino)- 4- fenyl- lH- pyrazolo[ 3, 4- b]-pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(3-hydroksymetylpiperidino)-4-f enyl-nikotinonitril (sm.p.: 150-153°C) og hydrazinhydrat.
Sm.p.: 210-212°C.
E ksempel 2 7
3- amino- 6- ( 3- hydroksypiperidino)- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(3-hydroksypiperidino) -4-f enyl-nikotinonitril (sm.p.: 183-185°C) og hydrazinhydrat.
Sm.p.: 225-227°C.
Eksempel 2 8
3- amino- 6-( 2- metylmorfolino)- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(2-metyl-morf olino) -4-f enyl-nikotinonitril (sm.p.: 173-176°C) og hydrazinhydrat.
Sm.p.: 176-179°C.
Eksempel 29
3- amino- 6-( 2, 6- dimetylmorfolino)- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(2,6-dimetyl-morf olino) -4-f enyl-nikotinonitril (sm.p. 165-178°C, isomerblanding) og hydrazinhydrat.
Sm.p.: 235-238°C under spaltning (hydroklorid).
Eksempel 30
3- amino- 4- fenyl- 6- tiomorfolino- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-4-fenyl-6-tiomorfolino-nikotinonitril (sm.p.: 165-167°C) og hydrazinhydrat. Sm.p.: 169-171°C..
Sm.p. for hydrokloridet: 258-262°C (spaltn.).
Eksempel 31
3- amino- 6-( 2, 6- dimetyltiomorfolino)- 4- fenyl- lH- pyrazolo[ 3, 4- b]-p yridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(2,6-dimetyltiomorfolino)-4-fenyl-nikotinonitril (sm.p.: 144-147°C)
og hydrazinhydrat.
Sm.p.: 190-192°C.
Eksempel 32
3- amino- 6-( i- oksydo- tiomorfolino)- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(1-oksydo-tiomorfolino)-4-fenyl-nikotinonitril (sm.p. 222-224°C) og hydrazinhydrat.
Sm.p.: 228-230°C.
E ksempel 33
3- amino- 6-( 2- metyl- l- oksydo- tiomorfolino)- 4- fenyl- lH- pyrazolo-[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(2-metyl-l-oksydo- tiomorfolino)-4-fenyl-nikotinonitril (sm.p.: 215-216°C)
og hydrazinhydrat.
Sm.p.: 243-245°C.
Eksempel 34
3- amino- 6-( 1, 1- dioksydo- tiomorfolino)- 4- fenyl- lH- pyrazolo[ 3, 4- b]-pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(1,1-dioksydo-tiomorfolino)-4-fenyl-nikotinonitril (sm.p.: 24C-242°C)
og hydrazinhydrat.
Sm.p.: 250-252°C.
Eksempel 35
3- amino- 4- fenyl- 6- piperazino- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(N-formyl-piperazino)-4-fenyl-nikotinonitril (sm.p.: 180-182°C) og hydrazinhydrat ved 150°C.
Sm.p. for dihydrokloridet: 263-265°C (fra absolutt etanolisk saltsyre).
Eksempel 36
3- amino- 6-( N- metylpiperazino)- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(N-metylpiperazino) -4-fenyl-nikotinonitril (sm.p.: 180-182°C) og hydrazinhydrat.
Sm.p.: 185-188°C.
E ksempel 3 7
3- amino- 6-( N- benzylpiperazino)- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-(N-benzyl-piperazino) -4-f enyl-nikotinonitril (sm.p.: 165-167°C) og hydrazinhydrat.
Sm.p.: 186-188°C.
Eksempel 38 '
3- amino- 4- fenyl- 6-( N- fenylpiperazino)- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-4-fenyl-6-(N-fenyl-piperazino)-nikotinonitril (sm.p.: 232-234°C) og hydrazinhydrat, men med 5-timers oppvarmning til 150°C.
Sm.p.: 224-227°C.
Eksempel 39
3- amino~ 4- fenyl- 6-( 1, 2, 3, 4- tetrahydroisokinolino)- lH- pyrazolo-[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-4-fenyl-6-(1,2,3,4-tetrahydroisokinolino-nikotinonitril (sm.p.: 159-161°C) og hydrazinhydrat.
Sm.p.: 163-167°C.
Eksempel 40
3- aminoj6- indolino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-indolino-4- fenyl-nikotinonitril (sm.p.: 213-215°C) og hydrazinhydrat. Sm.p.: 243-246°C (dioksan).
Ek sempel 41
6-( 3, 6- etylen- heksametylenimino)- 3- amino- 4- fenyl- lH- pyrazolo-[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 6-(3,6-etylen-heksametylenimino)-2-klor-4-f enyl-nikotinonitril (sm.p.: 136-138°C) og hydrazinhydrat.
Sm.p.: 241-243°C.
Eksempel 42
3- amino- 6- dipropylamino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-dipropylamino-4-fenyl-nikotinonitril (sm.p.: 120-122°C) og hydrazinhydrat. Sm.p.: 177-179°C (etylacetat).
Eksempel 4 3
3- amino- 6- diisobutylamino- 4- fenyl- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-diisobutylamino-4-fenyl-nikotinonitril (sm.p.: 100-102°C) og hydrazinhydrat.
Sm.p.: 132-134°C (etylacetat).
Eksempel 44
3-ami no- 4-( 4'- metoksyfenyl)- 6- piperidino- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-4-(4<1->metoksyfenyl)-6-piperidino-nikotinonitril (sm.p.: 189-190°C) og hydrazinhydrat.
Sm.p.: 211-213°C.
Eksempel 45
3- amino- 4-( 4'- metoksyfenyl)- 6- morfolino- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-4-(4<1->metoksyfenyl)-6-morfolino-nikotinonitril (sm.p.: 215-217°C) og hydrazinhydrat.
Sm.p.: 210-211°C.
E ksempel 46
3- amino- 4-( 4'- fluorfenyl)- 6- morfolino- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-4-(4'-fluor-fenyl)-6-morfolino-nikotinonitril (sm.p.: 225-227°C) og hydrazin-
hydrat.
Sm.p.: 195-197°C.
Eksempel 47
3- amino- 4-( 2'- fluorfenyl)- 6- morfolino- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-4-(2'-fluor-fenyl)-6-morfolino-nikotinonitril (sm.p.: 188-190°C) og hydrazin-
hydrat.
Sm.p.: 171-172°C (etylacetat).
Eksempel 4 8
3- amino- 4- ( 4'- klorfenyl)- 6- morfolino- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-4-(4'-klor-fenyl)-6-morfolino-nikotinonitril (sm.p.: 250-252°C) og hydrazin-
hydrat.
Sm.p.: 228-230°C.
Eksempel 49 . -
3- amino- 4- ( 3'- klorfenyl)- 6- morfolino- lH- pyrazolo[ 3, 4- b] pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-4-(31-klor- " fenyl)-6-morfolino-nikotinonitril (sm.p.: 189-191°C) og
hydrazinhydrat. Sm.p.: 178-180°C (etylacetat).
Eksempel 50
3- amino- 6- heksametylenimino- 4- ( 4 ' - metyl f enyl) - lH- pyrazolo [ 3, 4- b] - pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-6-heksa- " | metylenimino-4-(4'-metylfenyl)-nikotinonitril (sm.p.: 161-163°C) og hydrazinhydrat. Sm.p.: 210-212°C.
Eksempel 51
3- amino- 4- ( 4'- fluorfenyl)- 6- heksametylenimino- lH- pyrazolo[ 3, 4- b]-pyridin
Fremstilt analogt med eksempel 1 fra 2-klor-4-(4'-fluor-fenyl)-6-heksametylenimino-nikotinonitril (sm.p.: 160-162°C)
og hydrazinhydrat.
Sm.p.: 183-185°C.
Claims (1)
- Analogifremgangsmåte for fremstilling av fysiologisk aktive lH-pyrazolo[3,4-b]pyridiner med den generelle formelhvor R^ betyr en etylamino-, isopropylamino-, isoamylamino-, benzylamino-, dimetylamino-, dietylamino-, dipropylamino-, dibutylamino-, diisobutylamino-, N-metyl-cyklcheksylamino-, N-metyl-benzylamino-, diallylamino-, pyrrolidino-, heksametylenimino-, piperidino-, metylpiperidino-, hydroksymetylpiperidino-, hydroksypiperidino-, fenylpiperidino-, benzylpiperidino-, dimetylpiperidino-, morfolino-, metylmorfolino-, dimetyl-morfolino-, piperazino-, N-metylpiperazino-, N-fenyl-piperazino-, N-benzyl-piperazino-, tiomorfolino-, dimetyl-tiomorfolino-, 1-oksydo-tiomorfolino-, metyl-l-oksydo-tiomorfolino-, 1,1-dioksydo-tiomorfolino-, 1,2,5,6-tetrahydro-pyridino-, 1,2,3,4-tetrahydroisokinolino-, indolino- eller 3,6-etylen-heksametyleniminogruppe, R2 betyr et hydrogenatom, en metyl- eller benzylgruppe, og R^ betyr et hydrogen-, fluor- eller kloratom, eller en metyl- eller metoksygruppe, og fysiologisk forlikelige salter derav med uorganiske og organiske syrer, karakterisert ved at et pyridin med den generelle formel hvor R-, er som ovenfor angitt, R^' betyr en piperazinogruppe som i 4-stilling er beskyttet med en acylgruppe, eller har de ovenfor for R^ angitte betydninger, og X betyr en nukleofil utskiftbar gruppe, omsettes med et hydrazin med den generelle formel hvor R2 er som ovenfor angitt, og eventuelt overføres en erholdt forbindelse med den generelle formel I i sine fysiologisk forlikelige syreaddisjonssalter med uorganiske eller organiske syrer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19762643753 DE2643753A1 (de) | 1976-09-29 | 1976-09-29 | Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine |
Publications (3)
Publication Number | Publication Date |
---|---|
NO773327L NO773327L (no) | 1978-03-30 |
NO147913B true NO147913B (no) | 1983-03-28 |
NO147913C NO147913C (no) | 1983-07-06 |
Family
ID=5989097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO773327A NO147913C (no) | 1976-09-29 | 1977-09-28 | Analogifremgangsmaate for fremstilling av fysiologisk aktive pyrazolopyridiner |
Country Status (21)
Country | Link |
---|---|
US (3) | US4182887A (no) |
JP (1) | JPS5344588A (no) |
AT (1) | AT359064B (no) |
AU (1) | AU513406B2 (no) |
BE (1) | BE859152A (no) |
DE (1) | DE2643753A1 (no) |
DK (1) | DK143183C (no) |
ES (1) | ES462700A1 (no) |
FI (1) | FI61899C (no) |
FR (1) | FR2366290A1 (no) |
GB (1) | GB1552730A (no) |
GR (1) | GR64049B (no) |
IE (1) | IE45700B1 (no) |
IL (1) | IL52997A (no) |
LU (1) | LU78179A1 (no) |
NL (1) | NL7710573A (no) |
NO (1) | NO147913C (no) |
NZ (1) | NZ185292A (no) |
PT (1) | PT67091B (no) |
SE (1) | SE7710873L (no) |
ZA (1) | ZA775784B (no) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2643753A1 (de) * | 1976-09-29 | 1978-04-06 | Thomae Gmbh Dr K | Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine |
AR036873A1 (es) * | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
AR037233A1 (es) | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
CA2531619A1 (en) * | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
JP2007510747A (ja) * | 2003-11-10 | 2007-04-26 | シンタ ファーマシューティカルズ コーポレーション | ピリジン化合物 |
CN1984891B (zh) * | 2004-07-06 | 2012-08-08 | 弗·哈夫曼-拉罗切有限公司 | 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法 |
KR100881240B1 (ko) | 2004-07-06 | 2009-02-05 | 에프. 호프만-라 로슈 아게 | Nk-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법 |
MY145822A (en) * | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
ES2386027T3 (es) * | 2004-10-29 | 2012-08-07 | Abbott Laboratories | Inhibidores de quinasas novedosos |
DE102004061288A1 (de) | 2004-12-14 | 2006-06-29 | Schering Ag | 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel |
US7725056B2 (en) * | 2006-01-10 | 2010-05-25 | Ricoh Co., Ltd. | Triboelectric charging device and field assisted toner transporter |
US8536168B2 (en) * | 2007-03-15 | 2013-09-17 | Novartis Ag | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
EP2356117B1 (en) | 2008-11-20 | 2012-09-26 | Genentech, Inc. | Pyrazolopyridine pi3k inhibitor compounds and methods of use |
EP2789615B1 (en) | 2009-08-11 | 2017-05-03 | Bristol-Myers Squibb Company | Azaindazoles as Btk kinase modulators and use thereof |
US20220259199A1 (en) * | 2018-05-02 | 2022-08-18 | Jw Pharmaceutical Corporation | Novel heterocycle derivative |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2232038A1 (de) * | 1972-06-30 | 1974-01-10 | Hoechst Ag | 3-amino-1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine, ihre herstellung und verwendung |
DE2643753A1 (de) * | 1976-09-29 | 1978-04-06 | Thomae Gmbh Dr K | Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine |
US4048184A (en) * | 1976-11-15 | 1977-09-13 | E. R. Squibb & Sons, Inc. | 6-Phenyl-2H-pyrazolo[3,4-b]pyridines |
-
1976
- 1976-09-29 DE DE19762643753 patent/DE2643753A1/de not_active Withdrawn
-
1977
- 1977-09-07 FI FI772655A patent/FI61899C/fi not_active IP Right Cessation
- 1977-09-19 US US05/834,114 patent/US4182887A/en not_active Expired - Lifetime
- 1977-09-19 AT AT670077A patent/AT359064B/de not_active IP Right Cessation
- 1977-09-22 AU AU29037/77A patent/AU513406B2/en not_active Expired
- 1977-09-26 IL IL52997A patent/IL52997A/xx unknown
- 1977-09-26 LU LU78179A patent/LU78179A1/xx unknown
- 1977-09-27 GR GR54440A patent/GR64049B/el unknown
- 1977-09-28 NZ NZ185292A patent/NZ185292A/xx unknown
- 1977-09-28 DK DK428477A patent/DK143183C/da active
- 1977-09-28 GB GB40364/77A patent/GB1552730A/en not_active Expired
- 1977-09-28 NL NL7710573A patent/NL7710573A/xx not_active Application Discontinuation
- 1977-09-28 SE SE7710873A patent/SE7710873L/xx not_active Application Discontinuation
- 1977-09-28 IE IE1988/77A patent/IE45700B1/en unknown
- 1977-09-28 BE BE181275A patent/BE859152A/xx unknown
- 1977-09-28 NO NO773327A patent/NO147913C/no unknown
- 1977-09-28 ES ES462700A patent/ES462700A1/es not_active Expired
- 1977-09-28 ZA ZA00775784A patent/ZA775784B/xx unknown
- 1977-09-28 PT PT67091A patent/PT67091B/pt unknown
- 1977-09-28 JP JP11657277A patent/JPS5344588A/ja active Pending
- 1977-09-29 FR FR7729322A patent/FR2366290A1/fr active Granted
-
1979
- 1979-09-13 US US06/075,100 patent/US4260621A/en not_active Expired - Lifetime
- 1979-09-13 US US06/075,493 patent/US4224322A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
IE45700L (en) | 1978-03-29 |
US4260621A (en) | 1981-04-07 |
NO147913C (no) | 1983-07-06 |
PT67091A (de) | 1977-10-01 |
FR2366290B1 (no) | 1982-07-09 |
SE7710873L (sv) | 1978-03-30 |
IE45700B1 (en) | 1982-11-03 |
PT67091B (de) | 1979-09-12 |
ATA670077A (de) | 1980-03-15 |
NL7710573A (nl) | 1978-03-31 |
GR64049B (en) | 1980-01-19 |
IL52997A (en) | 1980-09-16 |
DK143183B (da) | 1981-07-13 |
JPS5344588A (en) | 1978-04-21 |
US4182887A (en) | 1980-01-08 |
DK428477A (da) | 1978-03-30 |
FI772655A (fi) | 1978-03-30 |
DK143183C (da) | 1981-11-16 |
NO773327L (no) | 1978-03-30 |
GB1552730A (en) | 1979-09-19 |
DE2643753A1 (de) | 1978-04-06 |
NZ185292A (en) | 1980-05-08 |
AU513406B2 (en) | 1980-11-27 |
AT359064B (de) | 1980-10-27 |
IL52997A0 (en) | 1977-11-30 |
LU78179A1 (no) | 1978-11-03 |
US4224322A (en) | 1980-09-23 |
ZA775784B (en) | 1979-06-27 |
ES462700A1 (es) | 1978-06-01 |
FI61899B (fi) | 1982-06-30 |
AU2903777A (en) | 1979-03-29 |
FI61899C (fi) | 1982-10-11 |
BE859152A (fr) | 1978-03-28 |
FR2366290A1 (fr) | 1978-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO147913B (no) | Analogifremgangsmaate for fremstilling av fysiologisk aktive pyrazolopyridiner | |
US3682930A (en) | 4(1-alkyl-4-piperidylidine)-4h-benzo {84,5{9 {0 cyclohepta {8 1,2{14 6{9 | |
NO864126L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive pyridon-derivater. | |
NO129205B (no) | ||
DE3782687T2 (de) | Aminoimidazochinolin-derivate. | |
DE69713255T2 (de) | Pharmazeutische Pyridin-Derivate, ihre Herstellungsverfahren und Zwischenprodukte dafür | |
AU679040B2 (en) | Pyrrolo-pyridine derivatives as dopamine receptor ligands | |
UA54449C2 (uk) | 3-заміщені похідні піридо[4',3':4,5]тієно[2,3-d]піримідину | |
US2467692A (en) | Naphthyridones and processes fob | |
US2965643A (en) | Derivatives of pyrazolo | |
Haas et al. | The synthesis of pyridine derivatives from 3‐formylchromone | |
NO151287B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 9-hydrazono-6,7,8,9-tetrahydro-4h-pyrido(1,2-a)-pyrimidinderivater | |
PT89468B (pt) | Processo para a preparacao de 6-fenil{di-hidro-3(2h)-piridazinonas substituidas e de composicoes farmaceuticas que as contem | |
LV10716B (en) | Novel derivatives of triazolopyridine and triazoloquinoline aminoalkylthio compounds, methods for preparation thereof, medicinal preparations containing same, their use as analgetics | |
MXPA01006967A (es) | Uso de derivados de pirimidina para la profilaxis y terapia de la isquemia cerebral. | |
US3960863A (en) | Pyrido[1,2-a]pyrimidinone derivatives | |
IE39066B1 (en) | Imidazo (4,5-b) pyridines | |
SU512704A3 (ru) | Способ получени замещенных в 5-ом положении 5,10-дигидро-11 н-дибензо (в,е) (1,4)диазепин-11-онов | |
US3850917A (en) | 5,7-diamino-substituted thiazolo(5,4-d)pyrimidines and salts thereof | |
US3636041A (en) | 4 5-dihydro-7h-thieno(2 3-c)thiopyrans | |
NO126084B (no) | ||
DK153487B (da) | Analogifremgangsmaade til fremstilling af 2-(perhydro-1,4-diazino)-pyrimidooe5,4-daapyrimidinderivater | |
JPS63310891A (ja) | 縮合ピリダジン化合物 | |
Ing | 129. The alkaloids of Anagyris foetida and their relation to the lupin alkaloids | |
NO165544B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktivt 2,3-dihydro-1-(8-methyl-1,2,4-triazolo-(4,3-b)pyridazin-6-yl)-4(1h)-pyridinon. |